Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jun 21;11:3619–3635. doi: 10.2147/OTT.S164597

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 Zhao et al. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

MiR-145 suppresses LSCC proliferation and invasion and promotes apoptosis by inhibiting MYO5A. (A) Proliferation rates of Hep-2 cells at various time points after transfection with either miR-145 mimic or an NC. (B) Proliferation rates of Hep-2 cells at various time points after transfection with either MYO5A siRNA or an NC. (C) Hep-2 cells were transiently transfected with miR-145 mimic or an NC and subjected to migration and invasion assays. Representative photographs and quantification are shown. Magnification: ×200. (D) Hep-2 cells were transiently transfected with MYO5A-specific or NC siRNA and subjected to migration and invasion assays. Representative photographs and quantification are shown. Magnification: ×200. (E) Representative graph of the percentage of Hep-2 cells in apoptosis after transfection with miR-145 mimic or an NC. (F) Representative graph of the percentage of Hep-2 cells in apoptosis after transfection with MYO5A-specific siRNA or an NC. (G) Caspase-3 activity in Hep-2 cells transfected with miR-145 mimic or an NC. (H) Caspase-3 activity in Hep-2 cells transfected with MYO5A-specific siRNA or an NC.

Note: ^*P<0.05.

Abbreviations: LSCC, laryngeal squamous cell carcinoma; NC, negative control; miR-145, microRNA-145; 7-AAd, 7-aminoactinomycin D; OD, optical density.

MiR-145 suppresses LSCC proliferation and invasion and promotes apoptosis by inhibiting MYO5A. (A) Proliferation rates of Hep-2 cells at various time points after transfection with either miR-145 mimic or an NC. (B) Proliferation rates of Hep-2 cells at various time points after transfection with either MYO5A siRNA or an NC. (C) Hep-2 cells were transiently transfected with miR-145 mimic or an NC and subjected to migration and invasion assays. Representative photographs and quantification are shown. Magnification: ×200. (D) Hep-2 cells were transiently transfected with MYO5A-specific or NC siRNA and subjected to migration and invasion assays. Representative photographs and quantification are shown. Magnification: ×200. (E) Representative graph of the percentage of Hep-2 cells in apoptosis after transfection with miR-145 mimic or an NC. (F) Representative graph of the percentage of Hep-2 cells in apoptosis after transfection with MYO5A-specific siRNA or an NC. (G) Caspase-3 activity in Hep-2 cells transfected with miR-145 mimic or an NC. (H) Caspase-3 activity in Hep-2 cells transfected with MYO5A-specific siRNA or an NC.

Note: ^*P<0.05.

Abbreviations: LSCC, laryngeal squamous cell carcinoma; NC, negative control; miR-145, microRNA-145; 7-AAd, 7-aminoactinomycin D; OD, optical density.